Humacyte, Inc.

Equities

HUMA

US44486Q1031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:16:57 2024-05-16 am EDT			5-day change	1st Jan Change
6.52 ^USD	+0.77%		+46.57%	+133.27%

May. 10	Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024
Mar. 28	Transcript : Humacyte, Inc. - Special Call

Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 07:13 am EDT

Humacyte, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 36.97 million compared to USD 19.83 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.19 a year ago.

Latest news about Humacyte, Inc.

Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024	May. 10
Transcript : Humacyte, Inc. - Special Call	Mar. 28
Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024	Mar. 22
Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	Mar. 22	MT
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	Mar. 08	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	Mar. 01	MT
Humacyte Prices $40.2 Million Share Offering	Mar. 01	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Feb. 09	MT
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	Feb. 09	DJ
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	Feb. 09	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	Feb. 09	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	Feb. 09	CI
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	Dec. 12	MT
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	Dec. 12	CI
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	Dec. 11	MT
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	Nov. 17	CI
Transcript : Humacyte, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	23-10-16	CI
Humacyte Jumps 8.2% After Hours Thursday; CEO Laura Niklason, CFO Dale Sander to Present at Cantor Global Healthcare Conference Sept. 28	23-09-22	MT

Chart Humacyte, Inc.

Duration

Period

More charts

Company Profile

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.47 USD

Average target price

7.667 USD

Spread / Average Target

+18.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMACYTE, INC.	+133.27%	770M
MODERNA, INC.	+31.89%	49.46B
IQVIA HOLDINGS INC.	+1.67%	42.58B
LONZA GROUP AG	+48.94%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+12.61%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-23.78%	18.64B
BIO-TECHNE CORPORATION	+8.06%	13.16B
MEDPACE HOLDINGS, INC.	+30.74%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.13%	12.1B

Other Biotechnology & Medical Research